All In Biotech

Drug Trial Radar · NCT00444275

Nexium (Esomeprazole) in Symptom Adapted Therapy in GERD Patients

A Randomized, Open, Parallel-group Study to Evaluate the Efficacy of Three Different Patient Management Strategies During a 12 Weeks Maintenance Phase Following an Initial 4-weeks Acute Treatment Phase in Subjects With Symptoms Thought to be GERD Related

Last checked: Nov 19, 2026Latest source record: Dec 11, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 3,029 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

3,029

Actual

Start

Mar 2007

Primary completion

Oct 2008

Study completion Oct 2008

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Mar 7, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To compare the efficacy of three different long-term treatment strategies of reflux disease in primary care setting.

Conditions

  • GERD

Interventions

  • esomeprazole (Nexium®)Drug

    This randomized study was conducted on parallel groups and included two phases: * One initial phase during when the patients received once daily, either esomeprazole 20 mg or esomeprazole 40 mg, depending on the investigator's decision * One maintenance treatment phase, patients were randomized to one of the following three groups, either esomeprazole 20 mg once daily, or esomeprazole 20 mg on demand or antacid treatment as needed

  • Xolaam®Drug

    This randomized study was conducted on parallel groups and included two phases: * One initial phase during when the patients received once daily, either esomeprazole 20 mg or esomeprazole 40 mg, depending on the investigator's decision * One maintenance treatment phase, patients were randomized to one of the following three groups, either esomeprazole 20 mg once daily, or esomeprazole 20 mg on demand or antacid treatment as needed

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Efficacy of Three Strategies of Long-term TreatmentTime frame: 16 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Research Site

    Rouen, France

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.